SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.

<h4>Background and objectives</h4>The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in ge...

Full description

Bibliographic Details
Main Authors: Alessandra Mangia, Valeria Piazzolla, Anna Giannelli, Egidio Visaggi, Nicola Minerva, Vincenzo Palmieri, Immacolata Carraturo, Domenico Potenza, Nicola Napoli, Gianfranco Lauletta, Vincenzo Tagarielli, Rosanna Santoro, Ernesto Piccigallo, Sergio De Gioia, Angelo Chimenti, Giuseppe Cuccorese, Antonio Metrangolo, Michele Mazzola, Ernesto Agostinacchio, Giuseppe Mennea, Carlo Sabbà, Marina Cela, Massimiliano Copetti, Ruggiero Losappio
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0215783

Internet

https://doi.org/10.1371/journal.pone.0215783

Similar Items